References
1.) Huang J, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol 2022; 9:e670-e677
2.) Puig N, et al. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma. Blood 2024; 144:2432-24382
The IVD EXENT product is only commercially available in certain countries and is not commercially available in the USA or China. Future commercial availability cannot be guaranteed. For product availability contact your local representative
EXENT, EXENT-iP, EXENT-iX, EXENT-iQ, and Optilite are registered trademarks of The Binding Site Group Limited (Birmingham, UK) in certain countries.
*) The EXENT Solution consists of the following CE marked products:
EXENT Analyser, IE800 (IVDR Class A, non-sterile).
Immunoglobulin isotypes (GAM) for the EXENT Analyser - MSR801.M (IVDR Class C).
EXENT Immunoglobulin Isotypes (GAM) Control Pack - MSQ801.M (IVDR Class C).
**) The EXENT System combines EXENT Analyser with the Immunoglobulin Isotypes (GAM) for the EXENT Analyser.
